TNIB ER (Tofacitinib (11mg))

Tnib 11mg Extended Release Tablet is indicated for the management of moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. This medication assists in alleviating pain, tenderness, and swelling in the joints by mitigating inflammation. Additionally, it plays a role in decelerating the deterioration of bone and joint health. Tnib can be taken as a standalone treatment or may be combined with other medications based on your specific health needs. The tablets are versatile in that they can be administered with or without food; however, it is advisable to take them at the same time daily for optimal results. The prescribed dosage may vary based on your medical condition and any other medications you may be using. Adhere strictly to your healthcare provider’s directions, and refrain from discontinuing the medication without their guidance, as this could exacerbate your condition. Routine blood tests may be necessary prior to the initiation of therapy, and this medication should not be started if there is an existing infection. It is important to discuss any history of tuberculosis, shingles, kidney or liver impairment, hepatitis B or C, or previous blood clots with your doctor prior to commencing treatment. Tnib may increase susceptibility to infections or aggravate preexisting infections, making it essential to avoid close contact with individuals carrying contagious illnesses such as chickenpox, measles, or influenza. This medication is not intended for individuals under the age of 18, nor should it be taken during pregnancy or while breastfeeding unless deemed necessary by a healthcare professional after considering the potential risks and benefits. Regular medical evaluations may be required during your treatment period.